NB11 Stock Overview
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Vaxart, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.66 |
| 52 Week High | US$1.33 |
| 52 Week Low | US$0.44 |
| Beta | 0.67 |
| 11 Month Change | 0.30% |
| 3 Month Change | 34.69% |
| 1 Year Change | -2.16% |
| 33 Year Change | -88.72% |
| 5 Year Change | 182.05% |
| Change since IPO | -4.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| NB11 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | -1.3% |
| 1Y | -2.2% | -15.4% | 13.9% |
Return vs Industry: NB11 exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: NB11 underperformed the German Market which returned 13.9% over the past year.
Price Volatility
| NB11 volatility | |
|---|---|
| NB11 Average Weekly Movement | 21.9% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: NB11's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NB11's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 109 | Steven Lo | vaxart.com |
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Vaxart, Inc. Fundamentals Summary
| NB11 fundamental statistics | |
|---|---|
| Market cap | €155.08m |
| Earnings (TTM) | -€70.48m |
| Revenue (TTM) | €12.98m |
11.5x
P/S Ratio-2.1x
P/E RatioIs NB11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NB11 income statement (TTM) | |
|---|---|
| Revenue | US$13.93m |
| Cost of Revenue | US$66.20m |
| Gross Profit | -US$52.27m |
| Other Expenses | US$23.39m |
| Earnings | -US$75.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -375.30% |
| Net Profit Margin | -543.21% |
| Debt/Equity Ratio | 5.3% |
How did NB11 perform over the long term?
See historical performance and comparison